BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dapagliflozin: Phase IIb/III data

Dapagliflozin is under FDA review to improve glycemic control in Type II diabetics with a Jan. 28, 2012, PDUFA date. In July, an FDA advisory committee voted 9-6 against approval of the product, citing safety concerns (see BioCentury, July 25). The compound is also under review...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >